This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Marfan syndrome마르팡증후군

ItemDetails
A. Classification codesICD-10: Q87.4 | Special Copayment Reduction: V186 | Re-certification cycle: 5 years
B. SynonymsNot applicable
C. Adult onsetMay also present and be diagnosed in adulthood — many patients undiagnosed in childhood are first confirmed in adulthood because of aortic root dilation or ocular symptoms; the risk of aortic complications peaks in adulthood
SectionSummary
1. History1896, first description by Marfan. 1955, McKusick characterizes it as a connective tissue disorder. 1991, discovery of the FBN1 gene. Diagnostic system established with the 2006 Ghent criteria and the 2010 revised Ghent criteria.
2. CausesAbnormal fibrillin-1 protein due to pathogenic variants in the FBN1 (15q21.1) gene → structural defects of extracellular matrix microfibrils, TGF-β signaling hyperactivation → damage to the aorta, lens zonules, and skeletal tissues.
3. GeneticsAutosomal dominant. About 75% inherited, about 25% de novo FBN1 variants. More than 1,000 pathogenic variants reported. Genotype-phenotype correlation limited, but the neonatal form is exceptionally severe.
4. General epidemiologyAbout 1/5,000–1/10,000 births. An estimated more than 300,000 people worldwide. No sex difference. Registered under Korean Special Copayment Reduction V186. Early diagnosis is key to preventing aortic complications.
5. PathophysiologyDefective fibrillin-1 from FBN1 → weakened microfibrillar network structure → TGF-β hyperactivation due to impaired release of the TGF-β latent complex (LLC) → apoptosis of aortic medial smooth muscle cells, degradation of elastic fibers → aortic root dilation and dissection.
6. SymptomsAortic root dilation and dissection (life-threatening), ectopia lentis, myopia, arachnodactyly, tall stature, pectus excavatum, scoliosis, spontaneous pneumothorax.
7. SignsWalker-Murdoch wrist sign, Steinberg thumb sign, arm span exceeding height, reduced upper segment/lower segment ratio, aortic root dilation on echocardiography, upward lens dislocation on slit lamp.
8. ScreeningBegins with family history + characteristic skeletal findings. Echocardiographic measurement of the aortic root, ophthalmic slit-lamp examination, calculation of the body composition index. Molecular genetic testing for confirmation or differentiation from similar syndromes.
9. Diagnosis2010 revised Ghent criteria: aortic root dilation/dissection + ectopia lentis (diagnostic on its own), or systemic score of 7 or more + aortic dilation/dissection. Confirmed by identification of an FBN1 variant.
10. TreatmentBeta-blockers and losartan (TGF-β inhibition) to slow the rate of aortic dilation. Prophylactic aortic surgery when aortic diameter ≥5.0cm (or growth rate >0.5cm/yr). Regular echocardiography, exercise restriction, ophthalmic surgery.
11. PrognosisAverage lifespan in the 40s if untreated. With prophylactic aortic surgery and medical treatment, life expectancy now approaches normal. Aortic dissection and rupture are the main causes of death.
12. PreventionGenetic counseling, prenatal and preimplantation genetic diagnosis, regular echocardiographic follow-up of patients with a family history, avoidance of high-intensity exercise and contact sports, intensive aortic monitoring during pregnancy.
13. References10 recent references (with PMID/DOI)

1. History

Marfan syndrome (MFS) was first described in 1896 when the French pediatrician Antoine Bernard-Jean Marfan presented the case of a 5-year-old girl characterized by abnormally long fingers and toes, excessive limb length, and joint laxity. Marfan called this "dolichostenomelia (long, thin limbs)". Over the following decades, involvement of various systems, such as aortic dilation, ectopia lentis, and dural ectasia, was additionally reported, expanding the clinical spectrum of the syndrome.

In 1955, the American Victor McKusick classified Marfan syndrome as a connective tissue disorder and systematically organized its involvement of three major systems, skeletal, cardiovascular, and ocular, laying the foundation for the modern diagnostic concept. McKusick's book Heritable Disorders of Connective Tissue (1956) became a milestone in Marfan syndrome research. In 1986 the Berlin nosology criteria were published, formalizing the clinical diagnostic system, and in 1996 the Ghent criteria (original Ghent nosology) were established, clarifying diagnostic criteria by organ system.

Molecular identification came in 1991 when Dietz et al. first showed that mutations in the FBN1 (fibrillin-1) gene (chromosome 15, 15q21.1) cause Marfan syndrome. Fibrillin-1 is a key constituent protein of extracellular matrix microfibrils, and since the 2000s a 'dual mechanism (structural + signaling)' has been identified, in which FBN1 deficiency causes weakening of microfibrillar structure together with hyperactivation of the TGF-β signaling pathway. In particular, Habashi et al. (2006) published a study showing that losartan (a TGF-β blocker) suppresses aortic lesions in a Marfan syndrome mouse model, providing the clinical rationale for TGF-β-targeted treatment strategies. In 2010, Loeys et al. published the revised Ghent nosology 2010, which strengthened aortic root dilation/dissection and ectopia lentis as core diagnostic criteria and introduced the systemic score system. These criteria are still used as the international standard diagnostic criteria.

2. Causes

The direct cause of Marfan syndrome is pathogenic variants in the FBN1 (fibrillin-1) gene located at 15q21.1 on the long arm of chromosome 15. FBN1 encodes fibrillin-1, a large glycoprotein of 2,871 amino acids, and this protein is a key component in the formation of the microfibrillar network of the extracellular matrix (ECM).

Fibrillin-1 is essential for maintaining the elastic fiber structure of the aortic media, providing mechanical support for the lens zonules (zonule of Zinn), and forming the microfibrillar framework of bone, cartilage, and skin. When the structure of fibrillin-1 becomes abnormal due to FBN1 variants, two complementary mechanisms explain the pathology of Marfan syndrome.

First, the structural defect mechanism: mechanical fragility of the microfibrillar network directly causes reduced tissue support, such as reduced elasticity and strength of the aortic wall, ectopia lentis, and dural ectasia. Second, the TGF-β signaling hyperactivation mechanism: fibrillin-1 normally binds the TGF-β latent complex (LTBP: latent TGF-β binding protein) and regulates TGF-β activation. With FBN1 deficiency, this binding weakens and TGF-β becomes abnormally hyperactivated. TGF-β hyperactivation promotes degeneration and dilation of the aortic media through apoptosis of medial smooth muscle cells, elastin fragmentation, and activation of matrix metalloproteinases (MMP). This mechanism is the therapeutic target of TGF-β signaling blockers such as losartan.

Missense variants are the most common type of FBN1 variant, and nonsense, splicing, small insertion/deletion, and large deletion variants are also reported. In particular, missense variants that alter cysteine residues in calcium-binding EGF-like domains (cbEGF) disrupt disulfide bond formation in fibrillin-1, severely damaging the protein structure, and are associated with severe phenotypes. Variants in non-calcium-binding EGF domains or in the central region of the molecule (exons 24–32) are associated with neonatal Marfan syndrome (neonatal MFS), a particularly severe variant form with early death.

3. Genetics

Marfan syndrome is an autosomal dominant genetic disease. In about 75% of patients, one parent has the same syndrome, and about 25% arise from de novo FBN1 variants. Because it is autosomal dominant, each child of an affected parent has a 50% recurrence risk.

The FBN1 gene is located at 15q21.1 on chromosome 15 and is a very large gene consisting of 65 exons. To date, more than 1,000 pathogenic variants have been registered in the FBN1 database (UMD-FBN1). Most are variants specific to each family (private), and there are no common founder variants. About 65–70% of variants are missense, and nonsense, splicing, and insertion-deletion variants make up the rest.

Genotype-phenotype correlation is incomplete, but some patterns are known. Variants occurring between exons 24 and 32 (the region associated with neonatal Marfan syndrome) cause neonatal Marfan syndrome (neonatal MFS), which shows severe heart valve regurgitation, skin laxity, and joint hyperlaxity from the neonatal period, with most patients dying of cardiopulmonary failure in infancy. In contrast, variants outside this region cause typical Marfan syndrome. Because expressivity is highly variable, clinical severity can differ even within a family with the same variant. Penetrance is very high (near-complete).

Syndromes clinically similar to Marfan syndrome (differential diagnosis) include Loeys-Dietz syndrome (TGFBR1/TGFBR2 variants), vascular Ehlers-Danlos syndrome (COL3A1 variants), the MASS phenotype (partially overlapping with MFS but without ectopia lentis or major aortic dilation), and isolated ocular Marfan syndrome (FBN1 variants, ectopia lentis only). These are differentiated using the 2010 revised Ghent criteria and molecular genetic testing.

4. General epidemiology

The birth prevalence of Marfan syndrome is reported as about 1/5,000–1/10,000 births. An estimated more than 3 million people are affected worldwide, making it relatively common among rare genetic diseases. There is no sex (male/female) difference, and it occurs in all ethnic groups and regions.

Published prevalence studies worldwide report about 1/5,000 in the United States, about 1/9,800 in the Netherlands, and about 1/9,600 in the United Kingdom. In Korea, accurate prevalence data are limited, but it can be estimated from the number of patients registered under Special Copayment Reduction V186. Because Marfan syndrome is quite often missed, the actual prevalence is presumed to be higher than reported figures. In particular, patients with mild phenotypes, de novo mutation patients without a family history, and patients not diagnosed in childhood sometimes first present in adulthood with aortic complications.

There are reports that the prevalence of Marfan syndrome is higher than in the general population among athletes, especially tall players in basketball, volleyball, swimming, and similar sports, and Marfan syndrome is an important cause of sudden death (aortic dissection/rupture) in this group. For this reason, some countries recommend pre-participation echocardiographic screening for elite athletes. The annual mortality of Marfan syndrome reaches 2–10% without treatment, and survival has improved greatly with early diagnosis and treatment.

5. Pathophysiology

The pathology of Marfan syndrome arises from the interaction of two mechanisms: abnormal microfibrillar structure due to defective fibrillin-1 from FBN1 and TGF-β signaling hyperactivation.

Mechanism of aortic lesions: the aortic media consists of lamellar units composed of elastic fibers, smooth muscle cells, collagen, and fibrillin-1 microfibrils. Normal fibrillin-1 forms microfibrils between the elastic fibers of these lamellae, maintaining the elasticity and mechanical strength of the aortic wall. With FBN1 deficiency, the microfibrillar network weakens and becomes vulnerable to mechanical damage from repeated blood pressure pulsations. At the same time, TGF-β hyperactivation promotes apoptosis and TGF-β-induced fibrosis in aortic medial smooth muscle cells, and elastic fibers are degraded by activation of MMPs (matrix metalloproteinases). As a result, dilation begins preferentially at the aortic root (sinus of Valsalva), and without treatment it progresses to aortic dissection (mainly Stanford type A, DeBakey type I/II) or rupture, threatening life.

Mechanism of ocular lesions: the lens zonules (zonule of Zinn) consist mainly of fibrillin-1 microfibrils. FBN1 deficiency weakens the zonules, causing partial or complete dislocation of the lens (upward dislocation is characteristic). Axial myopia is related to increased axial length of the eye, and retinal detachment, early cataract, and glaucoma may also be present.

Mechanism of skeletal lesions: fibrillin-1 is also distributed in the extracellular matrix of growth plate cartilage. TGF-β hyperactivation alters the chondrocyte differentiation program in the growth plate, causing excessive linear growth (arachnodactyly, tall stature). Formation of the thorax (pectus excavatum, pectus carinatum) and spine (scoliosis, kyphosis) is also affected.

Mechanism of dural ectasia: the dura consists of elastic fiber components including fibrillin-1, and FBN1 deficiency causes dilation of the lumbosacral dura (dural ectasia), which can cause spinal cord compression, low back pain, and radiating leg pain.

6. Symptoms

Marfan syndrome is a multisystem disease involving the skeletal, cardiovascular, ocular, pulmonary, skin, and other systems.

Cardiovascular system

This is the most important clinical problem. Aortic root dilation occurs in almost all patients, and without treatment it progresses to aortic valve regurgitation, aortic dissection, and aortic rupture, causing sudden death. The risk of dissection increases sharply when the aortic root diameter reaches 50mm or more. Mitral valve prolapse (MVP) and mitral regurgitation are present in about 50–80%, and tricuspid valve prolapse is not uncommon. Pulsatile headache and back pain may be symptoms of aortic dilation and require attention.

Skeletal system

Arachnodactyly (thin, long, hyperextensible fingers and toes), tall stature (height markedly greater than the mean for age or family), arm span exceeding height, abnormal upper limb-lower limb ratio (reduced upper segment/lower segment ratio because the upper arm is short while the lower limbs are overgrown), pectus excavatum or pectus carinatum, scoliosis or kyphosis, flat feet, and joint hyperlaxity appear.

Ophthalmology

Ectopia lentis occurs in about 60–70%, with upward dislocation being particularly characteristic. High myopia (axial myopia), retinal detachment, early cataract, and glaucoma are present. Reduced vision has a great impact on quality of life.

Lungs

Spontaneous pneumothorax occurs at a higher frequency than in the general population (about 4–11%). Restrictive pulmonary dysfunction due to chest wall deformity may also appear.

Dura and nerves

Lumbosacral dural ectasia is observed in about 63–92% and causes chronic low back pain, headache, radiating leg pain, and leg weakness. Arachnoid cysts are sometimes present.

Skin

Stretch marks (striae atrophicae) develop even without repeated pregnancies. The skin may be thin with increased elasticity.

7. Signs

Skeletal signs on clinical examination

Walker-Murdoch wrist sign: when the opposite wrist is encircled with the thumb and little finger of one hand, the two fingers overlap. It is an objective indicator of arachnodactyly. Steinberg thumb sign: when the hand is clenched, the thumb protrudes beyond the ulnar border of the palm. If these two signs are positive, they are reflected in the systemic score. Evaluation also includes arm span exceeding height by a factor of 1.05 or more, an upper segment/lower segment ratio of 0.85 or less in adults (European reference), inspection of pectus excavatum and pectus carinatum, and calculation of the chest index (pectus severity index). Scoliosis (Cobb angle) and joint hyperlaxity (Beighton score) are also recorded as examination findings.

Cardiovascular signs: on auscultation, an aortic regurgitation murmur (diastolic decrescendo murmur) and the mid-systolic click and late systolic murmur of mitral valve prolapse may be heard. Echocardiography is the most important tool for objective assessment of signs, evaluating the aortic root (sinus of Valsalva) diameter and ascending aortic diameter as Z-scores adjusted for body surface area. A Z-score of 2 or more is the criterion for abnormality.

Ocular signs: slit-lamp examination confirms lens dislocation and abnormal lens position (upward and superolateral dislocation characteristic). Ophthalmoscopy evaluates retinal detachment and fundus changes. Glaucoma is screened by intraocular pressure measurement.

MRI/CT signs: dural ectasia is measured on lumbosacral MRI. Aortic CT angiography (CTA) identifies the extent of dilation, dissection, and aneurysm along the entire aorta.

8. Screening

Screening for Marfan syndrome begins with clinical suspicion. Marfan syndrome is suspected in children or adolescents with tall stature, arachnodactyly, and scoliosis, in adults with unexplained aortic dilation or ectopia lentis, and when there is a family history of sudden death.

Initial screening tests: echocardiography (measurement of the aortic root Z-score) is the most important and central screening test. It is noninvasive and can accurately measure the aortic root diameter. Mitral valve prolapse and cardiac function are evaluated at the same time. Ophthalmologic examination (slit-lamp examination for lens dislocation, refractive errors) is also included in initial screening.

Family history-based screening: the same screening tests (echocardiography, ophthalmologic examination, evaluation of clinical diagnostic criteria) are performed in first-degree relatives (children, siblings, parents) of a patient with confirmed Marfan syndrome. In families with an identified FBN1 variant, targeted FBN1 genetic testing of family members can determine early whether they carry the variant.

Pre-participation sports screening: some sports medicine guidelines recommend pre-participation echocardiography and clinical evaluation for Marfan syndrome in tall athletes with arachnodactyly (basketball, volleyball, swimming, etc.). This can prevent sudden death from aortic dissection during high-intensity exercise in athletes with undiagnosed Marfan syndrome.

9. Diagnosis

2010 revised Ghent criteria

The revised Ghent nosology (2010), the current international standard diagnostic criteria, presents the following diagnostic pathways:

The systemic score consists of the thumb/wrist sign (3 points), chest wall deformity (2 points), joint hyperlaxity (1 point), dural ectasia (2 points), pectus excavatum (2 points), pectus carinatum (1 point), scoliosis/kyphosis (1 point), reduced elbow extension (1 point), characteristic facial features (1 point), skin striae (1 point), myopia (1 point), mitral valve prolapse (1 point), and others, with a maximum of 20 points. With 7 or more points accompanied by aortic dilation, Marfan syndrome can be confirmed.

Molecular genetic diagnosis

Pathogenic variants are identified by full-length sequencing of the FBN1 gene (NGS-based targeted panel or WES). Large deletions are detected by MLPA. If FBN1 variant testing is negative, gene panel testing for differential syndromes such as Loeys-Dietz syndrome (TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3) and vascular EDS (COL3A1) is performed.

10. Treatment

Drug therapy

Beta-blockers are the traditional treatment for slowing aortic dilation. Atenolol or propranolol is used; by lowering heart rate and blood pressure, they reduce the pulsatile load on the aortic wall and slow the rate of aortic dilation. Early administration from childhood has a long-term aortic protective effect.

Losartan is an angiotensin II receptor blocker that has been shown to improve aortic lesions in animal models of Marfan syndrome through a mechanism of inhibiting the TGF-β signaling pathway. In clinical trials (the Pediatric Heart Network study, the COMPARE study, etc.), its effect on slowing aortic dilation was similar to that of beta-blockers or partly superior in children. It can be used when beta-blockers are contraindicated or in combination. It is contraindicated in pregnancy because of the risk of fetal malformation.

Surgical treatment

Prophylactic aortic root replacement is performed at an aortic root diameter of ≥50mm (some guidelines also consider surgery at a growth rate >5mm/year, or at 45mm or more taking body habitus and family history into account). Surgical options include the Bentall procedure (mechanical valve + aortic conduit replacement) and valve-sparing aortic root reconstruction (the David procedure, or Yacoub remodeling). Valve-sparing surgery is preferred because it avoids the burden of anticoagulation associated with mechanical valve replacement. Emergency surgery is required when aortic dissection occurs.

Ophthalmological treatment

Treatments include lensectomy and intraocular lens implantation for ectopia lentis, scleral buckling and vitrectomy for retinal detachment, prescription of glasses and contact lenses for refractive errors, and medical and surgical treatment of glaucoma.

Other treatments

For scoliosis, bracing is considered at a Cobb angle of 25–40 degrees and surgical correction at 40 degrees or more. For pectus excavatum and pectus carinatum with severe functional impairment, the Nuss procedure or Ravitch procedure is performed. For dural ectasia, conservative treatment (physical therapy, pain management) is the rule.

Lifestyle guidance

High-intensity exercise (weight training, contact sports, isometric exercise) and participation in competitive sports are restricted. Low-intensity aerobic exercise such as swimming, walking, and light cycling is allowed. During pregnancy, intensive monitoring of aortic diameter (echocardiography every 2–3 months) is needed.

11. Prognosis

In studies from the pre-treatment era (before the 1970s), the average life expectancy of Marfan syndrome was about 40–50 years, markedly lower than the general population, and aortic dissection and rupture were the main causes of death. However, with the introduction of beta-blockers and prophylactic aortic surgery and advances in imaging monitoring, the life expectancy of appropriately treated patients now approaches that of the general population.

A natural history study published in 2011 (a reanalysis of data by Silverman et al.) confirmed that the life expectancy of treated Marfan syndrome patients improved from 45 years in 1972 to about 72 years from the 1990s on. Ten-year survival after prophylactic aortic surgery is reported to be more than 90%, and surgical mortality has fallen to 1–2% or less at experienced centers.

The main prognostic determinants are aortic root diameter, rate of aortic dilation, timing of surgery, and adherence to medical treatment. The larger the aortic diameter at diagnosis and the faster the rate of dilation (>5mm/year), the higher the risk of dissection. When mitral regurgitation has progressed severely, there is an additional surgical burden. Ocular complications (retinal detachment, glaucoma) affect visual prognosis, so early detection and treatment are important. Chronic pain due to dural ectasia is a long-term complication that reduces quality of life.

12. Prevention

Marfan syndrome is an autosomal dominant genetic disease, and prevention strategies consist of genetic counseling, prenatal and preimplantation genetic testing, and preventive management of complications.

Genetic counseling: patients and families are counseled on the autosomal dominant mode of inheritance and the 50% recurrence risk (in the patient's children). For patients with a de novo variant (both parents normal), the possibility of germline mosaicism (about 2–3%) is disclosed. In families with an identified variant, genetic testing and echocardiographic screening are strongly recommended for adult family members (children, siblings) who have not yet been tested.

Prenatal genetic diagnosis: when a pathogenic FBN1 variant has been identified, fetal FBN1 gene analysis is possible through CVS at 10–12 weeks of gestation or amniocentesis at 15–18 weeks. Because confirmation of the skeletal features of Marfan syndrome on prenatal ultrasound is limited, molecular diagnosis takes priority.

Preimplantation genetic testing (PGT-M): in Marfan syndrome patients who choose IVF, transmission to children can be prevented by selecting and transferring embryos that do not carry the FBN1 variant.

Prevention of aortic complications: early administration of beta-blockers or losartan after diagnosis, regular echocardiographic follow-up (once a year in adults, more often in children and those with rapid aortic dilation), and avoidance of high-intensity exercise and contact sports are the core of preventing aortic dissection. Optimizing the timing of prophylactic surgery (aorta ≥50mm or growth rate criteria) is directly linked to preventing dissection/rupture.

Management during pregnancy: in women with Marfan syndrome, the risk of aortic dissection increases during pregnancy because of increased cardiac output and hormonal changes. When the aortic diameter before pregnancy is 40mm or less, pregnancy is relatively permitted, with intensive monitoring by echocardiography every 2–3 months. At an aorta of 40–45mm or more, the risks of pregnancy are fully discussed, and pregnancy after prophylactic surgery is recommended. Losartan is stopped during pregnancy and switched to a beta-blocker.

13. References

  1. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476-485. PMID: 20591885
  2. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352(6333):337-339. PMID: 1852208
  3. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312(5770):117-121. PMID: 16601194
  4. Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J. 2013;34(45):3491-3500. PMID: 23999449
  5. Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med. 2014;371(22):2061-2071. PMID: 25405392
  6. Silverman DI, Burton KJ, Gray J, et al. Life expectancy in the Marfan syndrome. Am J Cardiol. 1995;75(2):157-160. PMID: 7810492
  7. Pyeritz RE. Marfan syndrome: 30 years of research equals 30 years of additional life expectancy. Heart. 2009;95(3):173-175. PMID: 18653559
  8. David TE, David C, Feindel CM, Manlhiot C. Reimplantation of the aortic valve at 20 years. J Thorac Cardiovasc Surg. 2010;139(3):S57-S59. PMID: 20167268
  9. Judge DP, Dietz HC. Marfan's syndrome. Lancet. 2005;366(9501):1965-1976. PMID: 16325700
  10. Franken R, den Hartog AW, Radonic T, et al. Beneficial outcome of losartan therapy depends on type of FBN1 mutation in Marfan syndrome. Circ Cardiovasc Genet. 2015;8(2):383-388. PMID: 25691688